Experiments point to new treatments for PKD

April 02, 2008

A family of small molecules called CFTR inhibitors show promising effects in slowing the progression of polycystic kidney disease (PKD), the most common genetic disease of the kidneys, according to preliminary research reported in the July 2008 issue of the Journal of the American Society Nephrology.

Although much more study is needed, CFTR inhibitors could provide a useful new approach for the treatment of PKD. "The CFTR inhibitors could be the basis of a lifelong treatment to slow renal cyst growth and decline in renal function, prolonging dialysis-free patient survival," comments Dr. Alan S. Verkman of University of California, San Francisco, School of Medicine.

Patients with PKD develop cysts on the kidneys, which progressively increase in size and number. The kidneys become enlarged, eventually leading to kidney failure. Previous research has suggested that the buildup of fluid in the cysts is related to chloride secretion, which is affected by the CFTR (cystic fibrosis transmembrane conductance regulator) gene. The researchers used automated "high-throughput" screening techniques to identify CFTR inhibitors that might affect cyst growth.

These screening studies identified two classes of small-molecule CFTR inhibitors that slowed the growth of renal cysts. The best inhibitor of each class was identified and shown to reduce the number and growth of cysts by more than 80 percent.

The inhibitors were then tested in mice that had been genetically altered to produce a condition similar to PKD. Animals treated with CFTR inhibitors for up to seven days had significantly slower cyst expansion and kidney enlargement, and better preservation of kidney function. There was no evidence of harmful effects on kidney function.

PKD is an incurable condition for which new treatments are urgently needed. If effective medications to reduce the rate of fluid buildup in cysts could be developed, they might provide an entirely new approach to treatment to slowing the progression of the disease.

The results show that CFTR plays a role in the growth of renal cysts, and suggest that CFTR inhibitors have potential as treatments to reduce cyst growth in PKD. However, much more research will be needed to see if drugs based on the CFTR blockers will be useful in human PKD.

"The mouse model of PKD is not the real human disease for many reasons, such as the more rapid progression of disease in mice," says Dr. Verkman. "Clinical trials will be needed to determine the efficacy of these compounds in human PKD."
-end-
This research was supported through grants from the National Institutes of Health (NIH), Cystic Fibrosis Foundation, and Polycystic Kidney Disease Foundation.

The study entitled, "Small Molecule CFTR Inhibitors Slow Cyst Growth in PKD" will be available online at http://jasn.asnjournals.org/ beginning on Wednesday, April 2, 2008 and in print in the July issue of the Journal of the American Society of Nephrology (JASN).

The American Society of Nephrology (ASN) is a not-for-profit organization of 11,000 physicians and scientists dedicated to the study of nephrology and committed to providing a forum for the promulgation of information regarding the latest research and clinical findings on kidney diseases. ASN publishes the Journal of the American Society of Nephrology (JASN), the Clinical Journal of the American Society of Nephrology (CJASN), and the Nephrology Self-Assessment Program (NephSAP).

American Society of Nephrology

Related Kidney Function Articles from Brightsurf:

Cancer drug can rebalance kidney function in a devastating genetic disease
Researchers at the University of Cambridge and the University of Zurich have discovered that a drug newly approved for cancer improves kidney dysfunction in a mouse model of Dent disease 2 and Lowe syndrome

SphingoTec's kidney function biomarker penKid® accurately detects acute kidney injury in infants
penKidĀ® (Proenkephalin), a unique biomarker for the real-time assessment of kidney function.

Use of cystatin C for precise assessment of kidney function and cardiovascular risk
In many situations, it is essential that the physician knows a patient's kidney function as precisely as possible.

Young sugarcane workers at high risk of kidney function decline
Researchers from the Center for Health, Work and Environment (CHWE) at the Colorado School of Public Health have published a paper in PLoS-ONE, studying the decline in kidney function for young, first-time sugarcane workers in Guatemala.

Protein levels in urine after acute kidney injury predict future loss of kidney function
High levels of protein in a patient's urine shortly after an episode of acute kidney injury is associated with increased risk of kidney disease progression, providing a valuable tool in predicting those at highest risk for future loss of kidney function.

Kidney function may affect risks associated with prescription opioids
Compared with other pain medications, prescription opioids were linked with higher risks of death and hospitalization, particularly with higher doses.

Comparing major adverse cardiovascular events among patients with diabetes, reduced kidney function treated with metformin or sulfonylurea
This observational study compared major cardiovascular events (including hospitalization for heart attack, stroke, transient ischemic attack or cardiovascular death) among patients with diabetes and reduced kidney function treated with metformin or a sulfonylurea (a class of drugs to treat diabetes).

Fluoride may diminish kidney and liver function in adolescents, study suggests
luoride exposure may lead to a reduction in kidney and liver function among adolescents, according to a study published by Mount Sinai researchers in Environment International in August.

Higher kidney function at dialysis start linked with greater risk of death in children
In an analysis of information on children with kidney failure who began dialysis in the United States between 1995 and 2015, the risk of death was 1.36 times higher among children with higher kidney function at dialysis initiation.

Indigestion remedy slows kidney function decline and improves survival in late-stage CKD
As chronic kidney disease (CKD) progresses, the kidneys become less able to maintain a healthy balance of acids in the body.

Read More: Kidney Function News and Kidney Function Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.